NFE2L2 and amyotrophic lateral sclerosis: These may integrate Nrf2 activation with antisense oligonucleotides, RNA-binding protein modulators, or mitochondrial enhancers, paving the way for mechanism-driven, disease-modifying therapies in ALS and related neurodegenerative disorders.